Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Par Drugs and Chemicals's EV-to-OCF or its related term are showing as below:
NSE:PAR'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.01 Med: 0 Max: 8.01
Current: 8.01
During the past 10 years, the highest EV-to-OCF of Par Drugs and Chemicals was 8.01. The lowest was 8.01. And the median was .
NSE:PAR's EV-to-OCF is ranked better than 56.36% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.21
vs NSE:PAR: 8.01
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Par Drugs and Chemicals (NSE:PAR) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Par Drugs and Chemicals's PE Ratio (TTM) for today is calculated as:
Par Drugs and Chemicals's share price for today is ₹136.60.
Par Drugs and Chemicals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11.779.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Par Drugs and Chemicals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Par Drugs and Chemicals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Par Drugs and Chemicals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Par Drugs and Chemicals's EV-to-OCF falls into.
Par Drugs and Chemicals's current Enterprise Value is ₹1,262 Mil.
Par Drugs and Chemicals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹ Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?
Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued.
The current stock price of ₹136.60 is trading 19.5% below its estimated GF Value™ of ₹169.72.
GuruFocus considers Par Drugs and Chemicals to be Modestly Undervalued.
Key valuation signals for NSE:PAR:
EV-to-OCF:
GF Value™: ₹169.72 vs. price of ₹136.60 (19.5% below fair value)
No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
86GF Score
Get the complete analysis for NSE:PAR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PAR has been successfully added to your 
